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Abstract
The aim of this study was to investigate the isolation and distribu-
tion rate of Candida spp. in blood cultures and evaluate antifungal
susceptibility during an 11-year period (1998–2008) at a tertiary-
care hospital. The causative species were as follows: Candida albi-
cans, 163 strains (64%); Candida parapsilosis, 35 strains (13.7%);
Candida glabrata, 25 strains (9.8%); Candida tropicalis, 19 strains
(7.4%); and other Candida spp., 13 strains (5.1%). Candidaemia is
predominantly caused by C. albicans. C. parapsilosis is the most
common non-albicans Candida isolated in neonatal intensive-care
units. All Candida isolates remain susceptible to amphotericin B,
whereas the highest degree of resistance was observed for azoles.
Keywords: Antifungals, Candida albicans, candidaemia,
epidemiology, non-albicans Candida
Original Submission: 10 November 2009; Revised
Submission: 25 January 2010; Accepted: 28 January 2010
Editor: E. Roilides
Article published online: 10 February 2010
Clin Microbiol Infect 2010; 16: 1378–1381
10.1111/j.1469-0691.2010.03193.x
Corresponding author: M. Christoﬁdou, University of Patras,
School of Medicine, Department of Microbiology, Rio Patras, Patras
26500, Greece
E-mail: christof@med.upatras.gr
Bloodstream infections (BSIs) are major causes of morbidity
and mortality in developed countries. Recent studies in the
USA have classiﬁed these infections as the eighth leading
cause of infant death and the tenth leading cause (3.4%) of
overall death. The incidence of Candida BSIs has doubled
during the past two decades [1], and Candida has become
the fourth most frequent pathogen, accounting for 8% of
cases of hospital-acquired sepsis [2]. Although Candida albi-
cans remains the most prevalent yeast causing candidaemia,
an increase in the number of cases caused by non-albicans
species has been also reported [3]. Risk factors for candi-
daemia include prolonged stay in intensive-care units
(ICUs), increased use of broad-spectrum antibiotics, treat-
ment with corticosteroid and antineoplastic agents, use of
central venous or other catheters, receipt of parenteral
nutrition, abdominal surgery, solid organ or bone marrow
transplantation, and the presence of haematological malig-
nancy.
An 11-year surveillance of candidaemia cases was carried
out in the University Hospital of Patras in southwestern
Greece. This is a 750-bed hospital with about 100 000
ambulatory visits and 52 000 admissions per year. It offers a
number of special services providing organ transplantation
(kidney), haematology/oncology (including stem cell trans-
plantation), infectious diseases, neurosurgery and intensive-
care (neonatal, paediatric, and general adult) facilities. Clinics
belong to four main departments: medical wards (internal
medicine, cardiology, nephrology, neurology, haematology/
oncology, and transplantation centre), surgical wards (general
surgery units, orthopaedics, obstetrics, neurosurgery, and
urology), an adult ICU, and a neonatal ICU. Determination
of candidaemia cases, relative prevalence and species distri-
bution, as well as susceptibility testing, was performed. An
episode of candidaemia was deﬁned as one or more positive
blood cultures for Candida spp. isolated from patients with
clinical signs of infection, according to the European Organi-
zation for Research and Treatment of Cancer [4]. Subse-
quent positive cultures from the same patient were deﬁned
as a new episode only if there was an interval of at least
12 weeks between the two episodes.
Candida isolation from blood cultures was performed with
BactAlert 3D (Organon Teknika, Lyon, France). All isolates
were identiﬁed using the germ-tube test and API32C system
(Bio-Merieux, Lyon, France). Antifungal susceptibility was
determined by Etest (AB Biodisk, Solna, Sweden) on RPMI–
2% glucose agar, and MICs of amphotericin B, 5-ﬂuorocyto-
sine, ketoconazole, itraconazole, ﬂuconazole, voriconazole,
posaconazole and caspofungin were evaluated according to
the manufacturer’s instructions. Resistance to 5-ﬂuorocyto-
sine was deﬁned as MIC ‡32 mg/L, resistance to ﬂuconazole
as MIC ‡64 mg/L, resistance to itraconazole as MIC ‡1 mg/L,
and resistance to voriconazole as MIC ‡4 mg/L, whereas the
MIC cut-off value for determination of resistance to caspo-
fungin was 2 mg/L, as proposed by Etest Interpretive Criteria
and in accordance with CLSI guidelines as described in M27-
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A2 (no interpretive breakpoints for caspofungin are included)
[5,6]. The MIC cut-off value for susceptibility to amphoteri-
cin B was 1 mg/L [5,7]. Isolates with MICs £1 mg/L were
considered to be susceptible to posaconazole [8] whereas
strains with MICs ‡1 mg/L were considered to be resistant
to ketoconazole.
At the clinical laboratory of the microbiology department,
151 399 blood cultures were processed. Among 13 417
positive blood cultures accounting for 7811 BSI cases, 438
were positive for Candida spp., reﬂecting 255 candidaemia
cases. No patient had more than one episode of candidaemia
during hospitalization. An increasing frequency of Candida BSI
during the study period was observed, varying from 1.33%
(eight cases) of all BSIs or 0.068% of all blood cultures in
1998, to 4.4% (47 cases) or 0.472% respectively in 2008.
C. albicans was the leading cause (163 cases; 64%), followed
by Candida parapsilosis (35 cases; 13.7%). Candida glabrata was
isolated from 25 cases (9.8%) and Candida tropicalis from 19
cases (7.4%). Other Candida species were isolated in 13
cases of candidaemia (5.1%). Relative frequencies were 1.56%
(four cases) for Candida guillermondii, 1.17% (three cases) for
Candida humicola, 0.78% (two cases each) for Candida lipolytica
and Candida lucitaniae, and 0.4% (one case each) for Candida
krusei and Candida stellatoida. During the study period, a
trend to Candida non-albicans spp. was observed between
2000 and 2003 (Fig. 1).
One hundred and six (106) candidaemia cases (41.6%)
originated in medical wards, 61 cases (23.92%) in surgical
wards, 61 cases (23.92%) in the neonatal ICU, and 27 cases
(10.6%) in the adult ICU. C. albicans was the most frequent
isolate in all departments, ranging from 58.5% in medical
wards to 77.7% in the adult ICU. C. parapsilosis had a high
incidence in the neonatal ICU (26.3%). C. glabrata was the
most common non-albicans Candida species in the adult ICU
(11.1%), and C. tropicalis was the most common in surgical
wards (11.5%). Other Candida spp. had a relatively high inci-
dence in medical wards (9.4%) (Table 1).
All strains were susceptible to amphotericin B. The high-
est resistance rates were observed for azoles, especially
itraconazole, ﬂuconazole, and ketoconazole. C. glabrata and
C. tropicalis demonstrated the highest rates of resistance to
azoles.
Although posaconazole is a relatively new azole that was
ﬁrst used in our setting in 2007, ﬁve of eight C. glabrata
strains (62.5%) were found to be resistant (Table 2). In
terms of antifungal consumption in our hospital, amphoteri-
cin B is considered to be the ﬁrst-choice agent, and caspo-
fungin is used as an alternative. Regarding azoles, ﬂuconazole
and, more recently, voriconazole and posaconazole are ﬁrst-
choice antifungal agents.
C. albicans represented more than half of all isolates, a
ﬁnding that is in accordance with most European studies [9–11],
in contrast to the USA [12] and Asia [13,14], where non-
albicans Candida spp. account for more than half of candida-
emia cases.
C. albicans predominated in all departments. C. parapsilosis
had a high incidence in the neonatal ICU, which is a consis-
tent ﬁnding in many studies [1,15–17] and may be attrib-
uted to the use of central venous catheters [18] and
parenteral alimentation in premature infants. In the adult
ICU, C. glabrata (11.1%) was the most common non-albicans
Candida sp., a ﬁnding that is in accordance with other stud-
ies [17,19]. In medical wards, a relatively high incidence of
not only C. parapsilosis, C. tropicalis and C. glabrata but also
of other uncommon Candida spp. was observed as com-
pared with other departments, and was associated with a
relatively low incidence of C. albicans (58.5%). This is proba-
bly because haematology patients were included in this
study, and it is well known that in such patients the preva-
lence of non-albicans Candida is relatively high [1,17,20]. In
agreement with other studies, the high incidence of C. tropi-
calis in surgical wards (11.5%) may be attributed to underly-
ing diseases of hospitalized patients [21]. Although C. krusei
has emerged as a quite common species in other settings
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FIG. 1. Candida albicans vs. non-albicans Candida distribution (%)
during the study period.
TABLE 1. Species and department distribution of Candida
bloodstream isolates
Species
Medical
wards,
no. (%)
Surgical
wards,
no. (%)
ICU,
no. (%)
Neonatal
ICU,
no. (%)
Candida albicans 62 (58.5) 42 (68.85) 21 (77.78) 38 (62.3)
Candida parapsilosis 13 (12.26) 5 (8.2) 1 (3.7) 16 (26.2)
Candida glabrata 12 (11.3) 5 (8.2) 3 (11.1) 5 (8.2)
Candida tropicalis 9 (8.5) 7 (11.4) 2 (7.4) 1 (1.6)
Candida spp. 10 (9.4) 2 (3.2) 0 (0) 1 (1.6)
ICU, intensive-care unit.
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[22,23], its incidence was very low in Patras University
Hospital.
Susceptibility data indicate that non-albicans Candida spp.,
with the exception of C. parapsilosis, are mainly resistant to
ﬂuconazole and to new azoles. Current guidelines regarding
the management of candidaemia in non-neutropenic patients
favour the use of an echinocandin for patients with moder-
ately severe to severe illness or recent azole exposure and
for identiﬁed C. glabrata candidaemia. Fluconazole is recom-
mended for less critically ill patients or those with no recent
azole exposure [24]. Therefore, species-directed therapy
should be administered in candidaemia cases.
As Candida BSIs demonstrate increasing prevalence, large
retrospective and guided epidemiological surveys using a
common database are needed to monitor trends in incidence
and changes in species distribution. Uniform therapeutic pro-
tocols based on meta-analyses should also be put in place in
order to optimize the control and prevention of Candida
infections.
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